# West Pharmaceutical Services **Source:** https://geo.sig.ai/brands/west-pharmaceutical-services **Vertical:** Healthcare Tech **Subcategory:** Pharmaceutical Packaging **Tier:** Leader **Website:** west-pharmaceutical-services.com **Last Updated:** 2026-04-14 ## Summary West Pharmaceutical Services (WST) reported ~$3.0B revenue in FY2024. Designs packaging components and delivery systems for injectable drugs — critical for vaccine and biologic drug manufacturing. HQ: Exton, PA. ## Company Overview West Pharmaceutical Services, Inc. is the global leader in packaging components and delivery systems for injectable medications, designing and manufacturing the stoppers, closures, caps, and drug delivery systems that seal vials, syringes, and cartridges containing vaccines, biologics, and injectable drugs. Every major pharmaceutical company and biologic manufacturer relies on West's containment solutions — the small rubber stopper sealing an mRNA vaccine vial or insulin cartridge is almost certainly a West product. West reported approximately $3.0 billion in revenue in FY2024, driven by its Proprietary Products segment — high-value elastomeric components, self-injection systems, and digital drug delivery technologies — and a Contract Manufactured Products segment. The company's competitive moat rests on regulatory entrenchment: once a drug is approved with West components specified in the FDA filing, substituting a competitor's stopper requires a costly and time-consuming regulatory resubmission. This creates switching costs that are near-permanent in practice. West experienced explosive demand during 2020–2022 as COVID vaccine manufacturers required massive volumes of stoppers and closures for global vaccine campaigns. Post-pandemic, the company is navigating a destocking cycle as customers work through excess component inventories. The long-term growth drivers remain intact: biologic drugs (which require sophisticated containment) are the fastest-growing pharmaceutical segment, self-injection devices (auto-injectors, wearables) are increasingly preferred by patients, and global vaccine manufacturing capacity continues expanding. ## Frequently Asked Questions ### What does West Pharmaceutical Services make? West makes rubber stoppers, aluminum seals, and plastic closures that seal drug vials and syringes, plus sophisticated self-injection devices like auto-injectors and wearable drug delivery systems for injectable medications. ### Why is West's business hard to replace? Once a drug is FDA-approved with West components specified in its regulatory filing, switching to a competitor requires an expensive, multi-year FDA resubmission. This regulatory lock-in creates near-permanent switching costs that give West exceptional customer retention. ### What is West Pharmaceutical's ticker? West Pharmaceutical Services trades on the NYSE under the ticker WST. ### How did COVID impact West's business? The COVID vaccine rollout generated extraordinary demand for West's vial stoppers and closures, driving revenue growth above 25% in 2021–2022. Post-pandemic destocking created a revenue headwind in 2023–2024 as customers consumed accumulated inventories. ### How does West's self-injection device business support GLP-1 drug delivery? GLP-1 drugs (Ozempic, Mounjaro) are primarily delivered via auto-injector pens — exactly the type of sophisticated drug delivery device West designs and manufactures. As GLP-1 drugs scale to massive volumes, West's auto-injector components face enormous demand growth. West also manufactures the primary rubber components (stoppers, plungers) for GLP-1 prefilled syringes. The GLP-1 market boom is a significant near-term growth driver for West beyond its traditional vial stopper business. ### What are West's SmartDose and SelfDose wearable drug delivery systems? West's SmartDose and SelfDose are wearable injector devices that deliver large-volume subcutaneous drug doses (2-10ml) over minutes to hours — enabling at-home administration of biologics that would otherwise require clinic infusions. These devices are critical for enabling biologic drugs (like high-concentration monoclonal antibodies) to be administered at home rather than in infusion centers, dramatically improving patient convenience and healthcare economics for payers. ### How does West's regulatory lock-in protect its business? When a biologic or injectable drug is FDA-approved, the stopper, plunger, and closure materials from West must be specified in the FDA filing. The biocompatibility testing, extractables and leachables studies, and compatibility validation between West's components and the drug formulation are extensive processes that take 2-5 years to complete. Once a drug is approved with West components, switching to another supplier requires repeating this validation and filing a supplemental NDA — a prohibitively expensive process that creates near-permanent customer relationships. ### What is West Pharmaceutical's financial profile and growth outlook? West Pharmaceutical Services (NYSE: WST) generates approximately $3B in annual revenue with operating margins in the high-teens to low-20% range. The business is driven by pharmaceutical industry volume growth — more injectable drugs, more biologics, more self-injection devices. Post-COVID destocking headwinds in 2023-2024 are expected to normalize as customer inventories deplete, returning West to its mid-single-digit organic growth trend. High-value products (HVP) — sophisticated stoppers with coatings that prevent drug interactions — drive margin expansion. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*